Abstract
1. Vasodepressor responses to intravenous (i.v.) injection of bradykinin (BK) and des-Arg9-BK, a selective B1 kinin receptor agonist, were characterized following i.v. pretreatment with selective B1 ([Leu8]-des-Arg9-BK) and B2 (Hoe 140) kinin receptor antagonists in anaesthetized dogs. 2. Des-Arg9-BK (0.05-3.3 nmol kg-1) produced dose-dependent decreases in mean arterial blood pressure with a ED50 0.4 nmol kg-1. The vasodepressor effects evoked by des-Arg9-BK (0.6 nmol kg-1) and BK (0.2 nmol kg-1) were greater after i.v. and i.a. injections, respectively. 3. The vasodepressor response to BK (0.6 nmol kg-1) but not to des-Arg9-BK (0.6 nmol kg-1) was significantly (P < 0.001) blocked by pretreatment with the B2 receptor antagonist, Hoe 140. 4. The vasodepressor response to des-Arg9-BK (0.6 nmol kg-1) but not to BK (0.6 nmol kg-1) was significantly (P < 0.001) reduced by pretreatment with the selective B1 receptor antagonist, [Leu8]-des-Arg9-BK. Although both B1 and B2 receptor antagonists caused a transient fall in blood pressure, their inhibitory action was unlikely to be related to a desensitization mechanism. 5. Inhibition of prostaglandin synthesis with indomethacin prevented the vasodepressor response induced by arachidonic acid (1 mg kg-1, i.v.) but not that to BK or des-Arg9-BK (0.6 nmol kg-1). 6. These results suggest, firstly, that the vasodepressor responses to i.v. BK and des-Arg9-BK are mediated by the activation of B2 and B1 receptors, respectively; secondly, that prostaglandins are not involved in the vasodepressor responses to kinins.(ABSTRACT TRUNCATED AT 250 WORDS)
Full text
PDF





Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bao G., Qadri F., Stauss B., Stauss H., Gohlke P., Unger T. HOE 140, a new highly potent and long-acting bradykinin antagonist in conscious rats. Eur J Pharmacol. 1991 Jul 23;200(1):179–182. doi: 10.1016/0014-2999(91)90684-i. [DOI] [PubMed] [Google Scholar]
- Barabé J., Marceau F., Thériault B., Drouin J. N., Regoli D. Cardiovascular actions of kinins in the rabbit. Can J Physiol Pharmacol. 1979 Jan;57(1):78–91. doi: 10.1139/y79-012. [DOI] [PubMed] [Google Scholar]
- Bhoola K. D., Figueroa C. D., Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992 Mar;44(1):1–80. [PubMed] [Google Scholar]
- Bouthillier J., Deblois D., Marceau F. Studies on the induction of pharmacological responses to des-Arg9-bradykinin in vitro and in vivo. Br J Pharmacol. 1987 Oct;92(2):257–264. doi: 10.1111/j.1476-5381.1987.tb11319.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Couture R., Mizrahi J., Regoli D., Devroede G. Peptides and the human colon: an in vitro pharmacological study. Can J Physiol Pharmacol. 1981 Sep;59(9):957–964. doi: 10.1139/y81-146. [DOI] [PubMed] [Google Scholar]
- Drapeau G., Chow A., Ward P. E. Metabolism of bradykinin analogs by angiotensin I converting enzyme and carboxypeptidase N. Peptides. 1991 May-Jun;12(3):631–638. doi: 10.1016/0196-9781(91)90112-3. [DOI] [PubMed] [Google Scholar]
- Drapeau G., deBlois D., Marceau F. Hypotensive effects of Lys-des-Arg9-bradykinin and metabolically protected agonists of B1 receptors for kinins. J Pharmacol Exp Ther. 1991 Dec;259(3):997–1003. [PubMed] [Google Scholar]
- Hock F. J., Wirth K., Albus U., Linz W., Gerhards H. J., Wiemer G., Henke S., Breipohl G., König W., Knolle J. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991 Mar;102(3):769–773. doi: 10.1111/j.1476-5381.1991.tb12248.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lembeck F., Griesbacher T., Eckhardt M., Henke S., Breipohl G., Knolle J. New, long-acting, potent bradykinin antagonists. Br J Pharmacol. 1991 Feb;102(2):297–304. doi: 10.1111/j.1476-5381.1991.tb12169.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lortie M., Regoli D., Rhaleb N. E., Plante G. E. The role of B1- and B2-kinin receptors in the renal tubular and hemodynamic response to bradykinin. Am J Physiol. 1992 Jan;262(1 Pt 2):R72–R76. doi: 10.1152/ajpregu.1992.262.1.R72. [DOI] [PubMed] [Google Scholar]
- Marceau F., Lussier A., Regoli D., Giroud J. P. Pharmacology of kinins: their relevance to tissue injury and inflammation. Gen Pharmacol. 1983;14(2):209–229. doi: 10.1016/0306-3623(83)90001-0. [DOI] [PubMed] [Google Scholar]
- Regoli D. C., Marceau F., Lavigne J. Induction of beta 1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur J Pharmacol. 1981 Apr 24;71(1):105–115. doi: 10.1016/0014-2999(81)90391-5. [DOI] [PubMed] [Google Scholar]
- Regoli D., Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980 Mar;32(1):1–46. [PubMed] [Google Scholar]
- Rhaleb N. E., Dion S., Barabé J., Rouissi N., Jukic D., Drapeau G., Regoli D. Receptors for kinins in isolated arterial vessels of dogs. Eur J Pharmacol. 1989 Mar 29;162(3):419–427. doi: 10.1016/0014-2999(89)90332-4. [DOI] [PubMed] [Google Scholar]
- Rhaleb N. E., Rouissi N., Jukic D., Regoli D., Henke S., Breipohl G., Knolle J. Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Qic8]bradykinin). Eur J Pharmacol. 1992 Jan 14;210(2):115–120. doi: 10.1016/0014-2999(92)90661-m. [DOI] [PubMed] [Google Scholar]
- Wirth K., Hock F. J., Albus U., Linz W., Alpermann H. G., Anagnostopoulos H., Henk S., Breipohl G., König W., Knolle J. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991 Mar;102(3):774–777. doi: 10.1111/j.1476-5381.1991.tb12249.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- van den Buuse M., Kerkhoff J. Interaction of bradykinin and angiotensin in the regulation of blood pressure in conscious rats. Gen Pharmacol. 1991;22(4):759–762. doi: 10.1016/0306-3623(91)90092-k. [DOI] [PubMed] [Google Scholar]